Top 20 global biopharma firms see 1.7 per cent market cap growth to $3.7 billion in 2024 amid policy challenges Read more
Budget expectations: Leaders opine for incentives in the nutra and API manufacturing sectors Read more
Novo Nordisk’s Ozempic gains USFDA approves to cut risk of diabetic kidney disease progression Read more